- Home
- HUMA
HUMA
Humacyte Inc.
as of 08-28-2026 3:46pm EST
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 191.4M | IPO Year: | 2020 |
| Target Price: | $6.19 | AVG Volume (30 days): | 8.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | annual |
| EPS: | -0.25 | EPS Growth: | 79.37 |
| 52 Week Low/High: | $0.53 - $2.55 | Next Earning Date: | 05-15-2026 |
| Revenue: | $2,038,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 444.16% | Revenue Growth (next year): | 248.39% |
| P/E Ratio: | -2.77 | Index: | N/A |
| Free Cash Flow: | -105926000.0 | FCF Growth: | N/A |
AI-Powered HUMA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Humacyte Inc. (HUMA)
Director
Avg Cost/Share
$0.69
Shares
10,000
Total Value
$6,930.00
Owned After
40,000
SEC Form 4
Director
Avg Cost/Share
$0.59
Shares
30,000
Total Value
$17,820.00
Owned After
40,000
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Jones Keith Anthony | HUMA | Director | Aug 20, 2026 | Buy | $0.69 | 10,000 | $6,930.00 | 40,000 | |
| Jones Keith Anthony | HUMA | Director | Aug 17, 2026 | Buy | $0.59 | 30,000 | $17,820.00 | 40,000 |
Earnings Transcripts
SEC 8-K filings with transcript text
2026 Q2 Q2 2026 Earnings
8-K Aug 12, 2026
Q2 2026 Earnings
8-KAug 12, 2026
Compare HUMA vs Leading Stocks
See how HUMA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "HUMA Humacyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.